Title:LncRNA MEG3: Targeting the Molecular Mechanisms and Pathogenic causes of Metabolic Diseases
Volume: 31
Issue: 37
Author(s): Yiyang Luo, Hailin Wang, Lijun Wang, Wei Wu, Jiale Zhao, Xueqing Li, Ruisi Xiong, Xueliang Ding, Ding Yuan*Chengfu Yuan*
Affiliation:
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional
Chinese Medicine, China Three Gorges University, Yichang, 443002, China
- College of Medicine
and Health Science, China Three Gorges University, Yichang, 443002, China
- Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional
Chinese Medicine, China Three Gorges University, Yichang, 443002, China
- Department of Biochemistry,
College of Basic Medical Science, China Three Gorges University, Yichang, 443002, China
Keywords:
MEG3, long non-coding RNA, metabolic diseases, inflammation, cancer, pancreatic β cells.
Abstract:
Background: Non-coding RNA is a type of RNA that does not encode proteins,
distributed among rRNA, tRNA, snRNA, snoRNA, microRNA and other RNAs
with identified functions, where the Long non-coding RNA (lncRNA) displays a nucleotide
length over 200. LncRNAs enable multiple biological processes in the human
body, including cancer cell invasion and metastasis, apoptosis, cell autophagy, inflammation,
etc. Recently, a growing body of studies has demonstrated the association of lncRNAs
with obesity and obesity-induced insulin resistance and NAFLD, where MEG3 is
related to glucose metabolism, such as insulin resistance. In addition, MEG3 has been
demonstrated in the pathological processes of various cancers, such as mediating inflammation,
cardiovascular disease, liver disease and other metabolic diseases.
Objective: To explore the regulatory role of lncRNA MEG3 in metabolic diseases. It provides
new ideas for clinical treatment or experimental research.
Methods: In this paper, in order to obtain enough data, we integrate and analyze the data
in the PubMed database.
Results: LncRNA MEG3 can regulate many metabolic diseases, such as insulin resistance,
NAFLD, inflammation and so on.
Conclusion: LncRNA MEG3 has a regulatory role in a variety of metabolic diseases,
which are currently difficult to be completely cured, and MEG3 is a potential target for
the treatment of these diseases. Here, we review the role of lncRNA MEG3 in mechanisms
of action and biological functions in human metabolic diseases.